Sechenov University together with their German colleagues have suggested a new highly sensitive, quick, and pain-free method for diagnosing kidney cancer. This method is based on measuring of the immune response to arrestin-1, a retina protein that is synthesized in the cancerous cells of kidneys.
Tumors can be benign or malignant. The first ones are not extremely dangerous but they can evolve into the latter ones, and those, in turn, are a cause of every sixth death in the world. Around 90-93% of all kidney growths turn out to be malignant, and there are currently no effective methods for early diagnostics. The initial stages of kidney cancer have no signs or specific symptoms, and therefore patients often get diagnosed with kidney cancer when it has already metastasized. At this point, the doctors make prognosis not about the possibility of recovery, but about a patient's life expectancy.
Radiofrequency Ablation (RFA) of Kidney Tumors
Radiofrequency ablation (RFA) is a medical procedure that uses electrical energy and heat to destroy cancer cells. Know more about the benefits and risks of RFA.
Advertisement
‘Antibodies to a retina protein to be used as a kidney cancer marker.’
Tweet it Now
Cancerous cells are the cells with considerable deviations in their behavior, such as abnormal division, development, or protein synthesis. Proteins may be synthesized in wrong quantities, in a wrong place, or they may be of a poor quality. Normally arrestin-1 is synthesized in the eye retina only, and its occurrence in another body organ may cause intensive autoimmune response (i.e. a reaction against the body's own proteins). It's already been discovered that arrestin-1 is present in melanoma (malignant skin tumor). However, the idea to check the kidney tumor cells for this type of protein and to measure the intensity of the immune response to it turned out to be new for the scientific world.
The scientists wanted to find out whether it is possible to use the antibodies to arrestin-1 as well as the protein itself as a marker of cancerous kidney diseases. To do so, they dyed tissue sections, carried out blood tests, and sequenced the samples. The samples for the experiment were collected from patients that suffered from malignant and benign kidney growths. The antibodies to arrestin-1 were found in the blood serum of 75% of the patients; the protein itself was identified in 90% of benign tumors and in over 50% of cancerous ones. Increased levels of arrestin-1 were also noticed in metastasis, especially in the brain metastasis.
![Renal Cell Carcinoma]( "Renal Cell Carcinoma")
Renal cell carcinoma is kidney cancer that affects the lining of the kidney tubules. The initial stages of the cancer are asymptomatic and this makes early management of the disease difficult.
All subtypes of kidney tumors synthesize arrestin-1, which makes this method inefficient for differential diagnostics. However, due to its high sensitivity to benign growths, the method helps diagnose a disease on early stages when the chances for recovery are at the highest. The diagnostic procedure is reduced to simple blood test for the antibodies to arrestin-1 instead of a biopsy that is technically complicated and painful for a patient.
"The discovery of arrestin-1 synthesis in cases of kidney cancer suggests the possibility of developing anti-cancer vaccines on the basis of this protein in the near future," says Andrey Zamyatnin, a co-author of the work, and the head of the Institute of Molecular Medicine at Sechenov University.
Source: Eurekalert
Renal Cell Carcinoma
Renal cell carcinoma is kidney cancer that affects the lining of the kidney tubules. The initial stages of the cancer are asymptomatic and this makes early management of the disease difficult.
Advertisement
All subtypes of kidney tumors synthesize arrestin-1, which makes this method inefficient for differential diagnostics. However, due to its high sensitivity to benign growths, the method helps diagnose a disease on early stages when the chances for recovery are at the highest. The diagnostic procedure is reduced to simple blood test for the antibodies to arrestin-1 instead of a biopsy that is technically complicated and painful for a patient.
"The discovery of arrestin-1 synthesis in cases of kidney cancer suggests the possibility of developing anti-cancer vaccines on the basis of this protein in the near future," says Andrey Zamyatnin, a co-author of the work, and the head of the Institute of Molecular Medicine at Sechenov University.
Source: Eurekalert
Test Your Knowledge on Kidney Cancer
Kidney cancer also called renal cancer is one of the top 10 most common cancers in both men and women. Kidney cancer mostly affects people above 65 years of age. There are four types of kidney cancer namely renal cell carcinoma, transitional cell carcinoma, Wilms tumor and renal sarcoma.
Advertisement
 Potential Therapeutic Strategy for Kidney Cancer Identified: StudyActivation of ISGF3 protein could be a novel therapeutic approach for patients with clear cell renal cancer, finds a new study. | Advertisement
|
Advertisement
Recommended Reading
Latest Cancer News
The mouse avatars created help study and develop personalized treatments against blood cancer - myeloma.
Chronotherapy (the sleep-wake cycle) is observed as a valuable alternative treatment in cancer diagnosis and treatment.
A nanoengineering platform targets neutrophils, the white blood cells without killing pancreatic cancer cells paving the way for effective treatments.
The mechanism by which the kinases cause inflammation has been discovered by scientists.
Pancreatic cancer cases are on the rise. The biomarker approach could reduce the chance of developing pancreatic cancer.